Clinical Research Papers:
A phase I clinical trial utilizing autologous tumor-infiltrating lymphocytes in patients with primary hepatocellular carcinoma
Metrics: PDF 1951 views | HTML 2604 views | ?
Shan-Shan Jiang1,*, Yan Tang1,*, Yao-Jun Zhang2,*, De-Sheng Weng1, Zhong-Guo Zhou2, Ke Pan1, Qiu-Zhong Pan1, Qi-Jing Wang1, Qing Liu1, Jia He1, Jing-Jing Zhao1, Jiang Li1, Min-Shan Chen2, Alfred E. Chang3, Qiao Li3, Jian-Chuan Xia1
1Department of Biotherapy, Sun Yat-sen University Cancer Center, State Key Laboratory of Oncology in South China, Collaborative Innovation Center for Cancer Medicine, Guangzhou, China
2Department of Hepatobiliary Oncology, Sun Yat-sen University Cancer Center, Guangzhou, China
3University of Michigan Comprehensive Cancer Center, Ann Arbor, Michigan, USA
*These authors have contributed equally to this work
Jian-Chuan Xia, e-mail: email@example.com
Qiao Li, e-mail: firstname.lastname@example.org
Keywords: primary hepatocellular carcinoma, autologous tumor-infiltrating lymphocytes, adoptive cell therapy
Received: July 15, 2015 Accepted: September 01, 2015 Published: October 20, 2015
This report describes an ongoing Phase I clinical trial testing the safety of adoptive cell therapy (ACT) using autologous tumor-infiltrating lymphocytes (TIL) in patients with primary hepatocellular carcinoma (HCC). Fifteen HCC patients were treated with their activated and expanded TILs following tumor resection. From a total of 17 patients with HCC, TIL were successfully expanded from 15 patients (88%), whereas two patients showed minimal or no expansion of TIL. Transient increase in the frequency of T cells was observed after adoptive transfer who was found only associated with grade I flu-like symptoms and malaise. After a median follow-up of 14 months, 15 patients (100%) were alive; and 12 patients (80%) showed no evidence of disease, 3 patients (patient 1,11,12) had tumor recurrence. The time to the diagnosis of tumor recurrence following therapy ranged from 105 to 261 days. These results indicate that immunotherapy with activated and expanded autologous TIL could be successfully performed with low toxicity, thus would serve as a novel treatment modality for patients with HCC.
All site content, except where otherwise noted, is licensed under a Creative Commons Attribution 3.0 License.